A breast cancer drug can reduce the risks of tumours returning.
A three-year study has found the drug, ribociclib, can reduce tumour reoccurrence by 25 per cent, if taken alongside traditional treatment.
The drug is usually used to treat women whose breast cancer has spread, but has now been found to benefit those in the early stages of the disease.
The study's findings were shown at the American Society of Clinical Oncology conference, in Chicago.
